Clinical trial
A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab…
NCT05882877 · Amgen, Industry · Active, not recruiting
Key facts
| NCT number | NCT05882877 |
|---|---|
| Title | A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) |
| Official title | A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) |
| Acronym | ROCKET-ASCEND |
| Lead sponsor | Amgen, Industry |
| Status | Active, not recruiting |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Atopic Dermatitis |
| Intervention type | Drug, Other |
| Interventions | Rocatinlimab, Placebo |
| Enrollment | 2,621 |
| Start date | May 31, 2023 |
| Primary completion | Jun 30, 2027 |
| Completion | Jun 30, 2027 |
| First posted | May 31, 2023 |
| Last update posted | Nov 3, 2025 |
| Countries | Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Croatia, Czechia, Denmark and 30 more |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: